Under the BioVersys and GSK collaboration agreement, GSK is evaluating the early bactericidal activity (EBA) of alpibectir-ethionamide (AlpE) in a pulmonary tuberculosis (TB) trial, in combination ...

BioVersys AG / Key word (s): IPO Bioversys announces partial exercise of over-allotment option 10-March-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is ...

1 Biosecurity Program, The Kirby Institute, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia 2 School of Population Health, Faculty of Medicine and Health, University ...

State of the Art Reviews are commissioned on the basis of their relevance to academics and specialists ... She has also received funding or in-kind support from Detmold, Sanofi, GSK, Merck, BioCSL, ...

Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines ... up 9.6p to 453.3p; and GSK, up 31p to 1,483.5p.

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...

The stock of GlaxoSmithKline Pharmaceuticals (GSK Pharma) hit a three-month high of ₹2,640 a share as it surged 5 per cent on Monday before closing at ₹2,638. During the past seven trading days, the ...

UPDATE: Now we know why this is happening so quietly: Microsoft says this free, ad-supported version of Office is only a test. Here’s the statement. –Paul “Microsoft has been conducting ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

President Donald Trump has warned a group of major U.S. drugmakers that his administration is set to impose tariffs on pharmaceutical goods, and they should start moving their manufacturing ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...